Semaglutide: a beginner-friendly guide to the GLP-1 behind Ozempic and Wegovy

Semaglutide is a once-weekly injectable medication in a class called GLP-1 receptor agonists. Your body already makes a hormone called GLP-1 (glucagon-like peptide-1), released by cells in the gut after you eat. GLP-1 tells your brain you are full, slows the rate at which your stomach empties, and prompts your pancreas to release insulin in response to glucose. Semaglutide is a long-acting laboratory version of that same signal.

It is the active ingredient in Ozempic, which the FDA approved for type 2 diabetes in 2017, and Wegovy, approved in 2021 specifically for chronic weight management in adults with obesity or with overweight plus a weight-related condition. The molecule is identical; the brand, dose ceiling, and FDA-approved indication are what differ. Both are made by Novo Nordisk, the Danish pharmaceutical company that has dominated GLP-1 research for two decades.

The reason the once-weekly format matters: native GLP-1 in your body has a half-life of about two minutes. Semaglutide is engineered with a fatty acid chain that binds to albumin in your blood, protecting it from being broken down and stretching the half-life to roughly seven days. That is the entire reason a single weekly injection can do the work that your body is doing in tiny pulses all day long.

When you eat, cells in your small intestine release GLP-1 within minutes. It then acts on receptors in three main places: your brain, your stomach, and your pancreas. Each effect contributes to a slightly different part of the picture, and together they produce what patients describe as the medication "quieting food noise."

In your hypothalamus and brainstem, GLP-1 receptors influence the circuits that control appetite and reward. Activation tends to make food less interesting between meals and reduces the size of the meals you do eat. Many patients report that they simply forget to think about food the way they used to — not because hunger is suppressed entirely, but because the loop of craving, planning, and snacking goes quiet.

In the stomach, GLP-1 slows gastric emptying. Food sits in your stomach longer, which prolongs the sensation of fullness from a given meal and blunts the post-meal blood sugar spike. This is also the mechanism behind the most common side effects — nausea, reflux, and feeling stuffed sooner than expected.

In the pancreas, GLP-1 amplifies glucose-dependent insulin secretion. Crucially, it only triggers insulin release when blood sugar is elevated, which is why GLP-1 medications carry a much lower hypoglycemia risk than older diabetes drugs like sulfonylureas.

GLP-1 was first identified in the 1980s by researchers studying gut peptides. The clinical interest was initially in diabetes — researchers noticed that people without diabetes secreted more insulin in response to oral glucose than to intravenous glucose, and the hunt for the responsible "incretin" hormones led to GLP-1.

The first GLP-1 drug to reach market was exenatide (Byetta), a synthetic version of a peptide originally isolated from the saliva of a Gila monster. It was approved in 2005 for type 2 diabetes and required twice-daily injections. Liraglutide (Victoza) followed in 2010 with once-daily dosing, and a higher-dose version (Saxenda) was approved for weight management in 2014.

Semaglutide arrived in 2017 with Ozempic, and the cultural moment hit in 2021–2023 as Wegovy data, off-label Ozempic prescribing, and high-profile users converged. By 2024, GLP-1 medications had reshaped the obesity-treatment landscape and prompted the most significant change in how clinicians think about weight management since the 1990s. The drugs are now being studied for effects on cardiovascular events, kidney disease, fatty liver disease, sleep apnea, and addictive behaviors — early data is generally positive, but most of those indications are still in trials.

Most patients start at 0.25 mg once weekly for four weeks. This starting dose is intentionally too low to produce much weight loss — it is a tolerance-building step designed to reduce nausea, which is the most common side effect. Skipping the starting dose to "go faster" is the single most reliable way to make yourself miserable for two weeks and want to quit.

After the four-week starter period, the dose typically steps up every four weeks: 0.5 mg, then 1.0 mg, then 1.7 mg, and finally a maintenance dose of 2.4 mg if you are on the Wegovy schedule. Ozempic tops out at 2.0 mg for diabetes, which is why people seeking weight effects sometimes ask their clinician about the higher-dose Wegovy formulation.

The injection itself is subcutaneous, similar to an insulin pen — you can inject in the abdomen, thigh, or upper arm. Most patients pick a consistent day of the week and treat it as a small ritual. If you miss a dose, the manufacturer guidance says you can take it within five days of the missed date; otherwise, skip it and resume on your normal day.

Once you reach the maintenance dose, you stay there indefinitely as long as the medication is working and tolerated. Some patients hold at a lower dose if the appetite effect is strong enough — there is no medal for being on the highest dose.

Weeks 1–4 (0.25 mg) are subtle. Most patients describe the experience as "I think something is happening" — slightly less interest in snacks, smaller dinners, mild fatigue some afternoons. The scale rarely moves meaningfully in this stretch, and that is by design.

Weeks 5–8 (0.5 mg, then 1.0 mg) are usually when the appetite shift becomes obvious. Portions get smaller without effort. The internal narrator that used to plan the next meal goes quiet. Patients report eating half of what they used to and feeling done. This is also where the scale typically starts to move, often one to three pounds per week in the early phase.

Weeks 9–12 (1.0–1.7 mg) tend to be the period of meaningful, visible loss. Total drop of 5–10% of body weight by week 12 is common for patients who tolerate the titration well, though the trial averages are based on much longer follow-up. Energy usually rebounds in this phase as your body adapts and you find an eating pattern that works.

Beyond week 12, the rate of loss generally slows but continues. The STEP-1 trial showed weight loss continuing through the 68-week study period before plateauing — meaning the most common reason people stop losing is not the drug failing, but discontinuation, dose interruption, or returning to old eating patterns once the appetite suppression normalizes.

The most common side effects are gastrointestinal. In trials, roughly 30–45% of patients reported nausea at some point, especially after a dose increase. Constipation, diarrhea, reflux, and a vague "stuffed" feeling after meals are also common. These typically peak in the first week after each dose step-up and then fade.

Practical management is mostly about eating smaller, more frequent meals; prioritizing protein and fiber; staying hydrated; and avoiding very greasy or rich foods during the adjustment window. Anti-nausea strategies that work for pregnancy or motion sickness — ginger, vitamin B6, slow eating — also tend to help here.

Less common but worth knowing: fatigue, headache, dizziness, and changes in taste. Some patients lose interest in foods they used to enjoy; others find that alcohol hits harder than expected. These are usually temporary.

Serious side effects are uncommon but real. Pancreatitis, gallbladder disease (especially gallstones, which can be triggered by rapid weight loss in general), and rare cases of bowel obstruction have been reported. There is also a class warning for medullary thyroid carcinoma based on rodent studies, which is why semaglutide is contraindicated in anyone with a personal or family history of MTC or multiple endocrine neoplasia type 2 (MEN2). Severe abdominal pain that does not resolve is always a reason to stop dosing and get evaluated.

Wegovy is FDA-approved for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition (such as type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). It is also approved for adolescents 12 and older meeting similar criteria.

It is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or MEN2, anyone with a known hypersensitivity to semaglutide, and during pregnancy. The manufacturer recommends discontinuing semaglutide at least two months before a planned pregnancy because of the long half-life.

Caution is warranted in patients with a history of pancreatitis, gastroparesis (semaglutide further slows gastric emptying), severe gastrointestinal disease, or a current eating disorder. The appetite-suppressing effect can be problematic for patients with a history of restrictive eating, and a thoughtful clinician will screen for that before prescribing.

The medication can be used in patients with type 2 diabetes (this is its original indication, after all), and offers blood sugar improvements alongside weight loss. In patients without diabetes, the goal is purely weight management and improved metabolic health.

Semaglutide is most accurately described as a chronic medication for a chronic condition. Studies of patients who stop the medication consistently show that most regain a significant portion of the weight they lost within a year. The body re-adapts: appetite normalizes, food noise returns, and the scale moves back toward its previous setpoint. This is not a moral failing — it is the same principle that makes blood pressure medication a long-term commitment.

That reality has two implications. First, going on semaglutide is a decision to take a medication for the foreseeable future, not a 12-week intervention. Second, the patients who do best treat the on-medication phase as a window to rebuild the structural habits that will outlast the prescription if they ever do stop: regular strength training (to preserve muscle, which the medication does not protect), sufficient protein intake (often 1.2–1.6 g per kg of body weight per day), reasonable sleep, and a sustainable eating pattern they can imagine doing forever.

The medication makes those habits feel possible — appetite is no longer fighting you, willpower is not the bottleneck, and you have the energy and headspace to actually plan and prepare meals. The most common regret patients report is not building those habits during the easy window, then being surprised when the work resumes after discontinuation.

For most people, the right framing is not "How long will I take this?" but "What is my plan if I ever come off?" If the answer is "I have no plan," the medication is doing all the work, and that is a fragile position to be in.

The cash list price of Wegovy in the United States in 2026 is around $1,300 per month, and Ozempic sits in a similar range. For patients with commercial insurance that covers obesity treatment, out-of-pocket costs are typically much lower — often $25 to $100 per month after a prior authorization is approved. For patients without coverage, the manufacturer offers a savings card that can lower the cash price substantially for commercially insured patients whose plan does not cover the medication. Uninsured patients with financial need may qualify for the Novo Nordisk patient assistance program, which can provide the medication at no cost in some cases.

Medicare Part D coverage for GLP-1s used for weight loss is still limited because of a long-standing statutory carve-out for obesity drugs. The 2024 expansion of the Wegovy label to include cardiovascular risk reduction in patients with established cardiovascular disease opened a partial path to Medicare coverage for that specific population. Patients without that indication may still be paying out of pocket through Medicare.

Outside the United States, pricing varies enormously. In several European countries, semaglutide for weight management is available through national health systems at a fraction of the U.S. cash price. The U.S. pricing has been the subject of congressional hearings and ongoing political debate, but the situation patients face today is what they face today — and the practical move is to know your insurance, ask about prior authorization early, and plan for a months-long process rather than expecting a same-week prescription.

A few practical tips for navigating the cost question. First, check your insurance formulary directly before scheduling the appointment, not after. Second, ask the prescribing clinic whether they have a dedicated team that handles prior authorizations and appeals — clinics that handle obesity medication routinely tend to have this dialed in. Third, if your initial PA is denied, ask for the specific reason and request an appeal; many initial denials are reversed on appeal with the right documentation.